UroToday8d
'Unfavorable Histology’ Classification Aims to Reduce Unnecessary Treatment, Journal Club - Jesse McKenney & Cornelia Ding
Matthew Cooperberg hosts a discussion with Jesse McKenney and Cornelia Ding about research on prostate cancer grading, presented in a paper proposing a new definition of adverse pathology. Dr.
UroToday12d
SUO 2024: Setting the Stage: Our Current Options for BCG Unresponsive NMIBC
(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), ...
UroToday12d
SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday12d
SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday13d
SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday6d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
UroToday12d
SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radical Prostatectomy
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Behfar ...
UroToday13d
SUO 2024: Phase 1B/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...
UroToday12d
SUO 2024: Novel Approaches to Radiotherapy to Reduce Patient Burden
ADT (including second generation agents), pelvic nodal radiotherapy, hydrogel placement, and boosting dominant nodules were allowed per investigator discretion. The results demonstrated that ...
UroToday13d
SUO 2024: Classification of Adverse Events after Prostate Cancer Hydrogel Perirectal Spacer Insertion Using Large Language Models
SUO annual meeting included a prostate cancer session, featuring a presentation by medical student Nishan Sohoni discussing the classification of adverse events after prostate cancer hydrogel ...
UroToday6d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: EMBARK in the PSMA PET Era and Ongoing Trials
This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
UroToday13d
SUO 2024: The Impact of BCG Shortage on Disease Recurrence for Patients with Non-Muscle Invasive Bladder Cancer: A SEER Patterns of Care Analysis.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Abstract/Posters Session. Dr Madison Wahlen discussed ...